Central adiposity measures are strongly associated with psoriasis risk, with a stronger association in women, according to a ...

A retrospective analysis of US medical records of people aged 65-95 years finds those with psoriasis on systemic therapies ...

SPARC tumbled 19 percent after Phase 2 trials of its psoriasis drug SCD-044 failed to meet primary endpoints. The company ...

New psoriasis drug Zoryve approved. How to use & why Black American participation in clinical trials is vital for health ...

The shares of Sun Pharma Advanced Research fell as much as 20% to Rs 156.14 apiece, the lowest level since May 16.

Sun Pharma’s phase 2 trials of SCD-044 to treat moderate to severe psoriasis and atopic dermatitis fails to meet primary endpoint: Our Bureau, Mumbai Wednesday, June 4, 2025, 11 ...

Both mild and moderate-to-severe psoriasis are significantly associated with an increased risk for sleep disorders, according ...

Sun Pharma disclosed that the drug did not meet primary endpoints in either study and as a result, the development of the SCD ...

SPARC share price plunged 20% following poor Phase 2 trial outcomes for SCD-044. The stock peaked at ₹186 but fell to ₹156.50 ...

Adults with plaque psoriasis aged 65 years and older had similar responses to IL-17 and IL-23 inhibitors to that of younger adults.

By Dennis Thompson HealthDay ReporterTHURSDAY, May 29, 2025 (HealthDay News) — Belly flab appears to be a stronger warning ...

May 27, 2025 — Researchers have found that central body fat, especially around the abdomen, is more strongly linked to psoriasis risk than total body fat, particularly in women. This link ...